<DOC>
	<DOC>NCT02665637</DOC>
	<brief_summary>This is a double-blind, two-arm, parallel-group, single-dose study.</brief_summary>
	<brief_title>Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed Herceptin</brief_title>
	<detailed_description>This is a double-blind, two-arm, parallel-group, single-dose study. A total of 70 healthy male subjects will be enrolled.</detailed_description>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1. Healthy male subject 2. Subject voluntarily agrees to participate in this study 1. Female. 2. Subject has a medical condition of disease including one or more. 3. Smoker</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>